As therapeutic anti‐RSPO antibodies already exist and anti‐RSPO3 has been demonstrated to be well tolerated in a clinical trial for colon cancer, realistic and relatively fast opportunities lie ahead to explore RSPO targeting in breast cancer patients. Here, RSPO3 is linked to breast cancer.